Abstract
Febrile neutropenia (FN) is one of the commonest complications of antineoplastic chemotherapy. New antimicrobials and new strategies created by the EORTC Antimicrobial and Invasive Fungal Infections cooperative groups, and MASCC (Multinational Association of Supportive Care in Cancer) [1 /14] have been successful in decreasing the mortality from 15 /20% in 1960 /1980 to 2 /5% in 2000 / 2004 [12 /14]. Within last 5 years however many new strategies were introduced. Here are the most frequently asked questions/FAQs concerning FN:
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
